InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.037 0.007 (23.33%)+
Announcement
Release
28 Jan 2026 9:37AM
Price at Release
$0.030
Full Release
download
Summary
The Investor Presentation by Patrys Limited focuses on the reformulation and development of a novel injectable format of quetiapine, known as AQS, to address unmet needs in the treatment of delirium. Delirium, a severe and acute mental disturbance with significant prevalence in ICU, palliative, and aged care settings, lacks approved treatments, with existing options often used off-label and presenting serious limitations. Patrys aims to introduce AQS as a faster-acting and more effective alternative, leveraging regulatory pathways for expedited market entry. The presentation outlines the clinical development stages, competitive advantages, market opportunity, and strategic partnerships, highlighting AQS's potential to improve patient care and reduce hospital costs.
Key Points
  • Patrys Limited is developing AQS, an injectable quetiapine formulation.
  • AQS targets unmet needs in delirium treatment, prevalent in ICU and aged care.
  • Current treatments are often off-label with significant limitations.
  • AQS offers rapid onset, high bioavailability, and customizable dosing.
  • The reformulation uses regulatory pathways for faster market approval.
  • Intellectual property protection includes a provisional patent.
  • Strategic partnerships sought with companies in CNS and hospital markets.
  • Market opportunity estimated at over US$2 billion annually.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.